The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Cognitive Enhancers as Adjuncts to Psychotherapy: Use of D-Cycloserine in Phobic Individuals to Facilitate Extinctionof Fear
Abstract
BACKGROUND: Traditional pharmacological approaches to treating psychiatric disorders focus on correcting presumed biochemical abnormalities. However, some disorders, particularly the anxiety-related disorders exemplified by specific phobia, have an emotional learning component to them that can be facilitated with psychotherapy. OBJECTIVE: To determine whether D-cycloserine (DCS), a partial agonist at the N-methyl-d-aspartate receptor that has previously been shown to improve extinction of fear in rodents, will also improve extinction of fear in human phobic patients undergoing behavioral exposure therapy. DESIGN: Randomized, double-blind, placebo-controlled trial examining DCS vs placebo treatment in combination with a precisely controlled exposure paradigm. SETTING: Participants were recruited from the general community to a research clinic. PARTICIPANTS: Twenty-eight subjects with acrophobia diagnosed by the Structured Clinical Interview for DSM-IV were enrolled. INTERVENTIONS: After we obtained pretreatment measures of fear, subjects were treated with 2 sessions of behavioral exposure therapy using virtual reality exposure to heights within a virtual glass elevator. Single doses of placebo or DCS were taken prior to each of the 2 sessions of virtual reality exposure therapy. Subjects, therapists, and assessors were blind to the treatment condition. Subjects returned at 1 week and 3 months posttreatment for measures to determine the presence and severity of acrophobia symptoms. MAIN OUTCOME MEASURES: Included were measures of acrophobia within the virtual environment, measures of acrophobia in the real world, and general measures of overall improvement. An objective measure of fear, electrodermal skin fluctuation, was also included during the virtual exposure to heights. Symptoms were assessed by self-report and by independent assessors at approximately 1 week and 3 months posttreatment. RESULTS: Exposure therapy combined with DCS resulted in significantly larger reductions of acrophobia symptoms on all main outcome measures. Subjects receiving DCS had significantly more improvement compared with subjects receiving placebo within the virtual environment (1 week after treatment, P</=.001; 3 months later, P</=.05). Subjects receiving DCS also showed significantly greater decreases in posttreatment skin conductance fluctuations during the virtual exposure (P</=.05). Additionally, subjects receiving DCS had significantly greater improvement compared with subjects receiving placebo on general measures of real-world acrophobia symptoms (acrophobia avoidance [P</=.02], acrophobia anxiety [P</=.01], attitudes toward heights [P</=.04], clinical global improvement [P</=.01], and number of self-exposures to real-world heights [P</=.01]); the improvement was evident early in treatment and was maintained at 3 months. CONCLUSION: These pilot data provide initial support for the use of acute dosing of DCS as an adjunct to exposure-based psychotherapy to accelerate the associative learning processes that contribute to correcting psychopathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DCS is an agonist of the N-methyl-D-aspartate (NMDA) glutamate receptor, and it has been shown to increase the efficacy of exposure therapies for a number of anxiety disorders (Hofmann, Sawyer, and Asnaani, 2012; Ressler, Rothbaum, Tannenbaum, Anderson, et al. 2004).”
From Advancing the treatment of anxiety disorders in transition‐age youth: a review of the therapeutic effects of unconscious exposure. (2025) · cites this paper as Ressler, Rothbaum, Tannenbaum, Anderson, et al. 2004
In the citing paper
“Participants who received the drug (oral administration two to four hours before each session) showed greater improvements than those who received a placebo.”
From Mediators and Mechanisms of Change in Psychotherapy Research (2007) · cites this paper as Ressler et al. 2004
In the citing paper
“The effects were evident one week and three months after treatment.”
From Mediators and Mechanisms of Change in Psychotherapy Research (2007) · cites this paper as Ressler et al. 2004
In the citing paper
“Recently, DCS combined with imaginal or virtual reality exposure (VRE) therapy has been shown to reduce length of treatment for some anxiety disorders, including acrophobia (Ressler et al, 2004), social phobia (Guastella et al, 2008; Hofmann et al, 2006), and panic disorder (Otto et al, 2010), which, like PTSD, include learned avoidance and cued emotional distress as salient symptoms.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“The choice of dosing regimen for our studies was based on the Ressler et al (2004) study, which showed that there was no difference in efficacy between the 50 and 500 mg dose of DCS on enhancing exposure therapy outcomes.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al (2004)
In the citing paper
“We chose weekly dosing, administered 90 min before exposure sessions, as this regimen has been effective in multiple animal and human fear extinction studies (Ledgerwood et al, 2003; Ressler et al, 2004; Walker et al, 2002)”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“These pilot data add to the literature showing that DCS-enhanced exposure therapy is effective for the treatment of anxiety disorders (Hofmann et al, 2006; Ressler et al, 2004).”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“Our data, in conjunction with that of Ressler et al (2004), Hofmann et al (2006), and Otto et al (2010), form a compelling pattern of evidence supporting the hypothesis that DCS may facilitate extinction learning.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“Shortly thereafter, several groups reported that DCS administration before or after exposure therapy, a form of treatment based on the principles of fear extinction learning, was effective in alleviating the symptoms of acrophobia (67), panic disorder (68), social anxiety disorder (69, 70), and obsessive–compulsive disorder (71–73).”
From Conditioned fear associated phenotypes as robust, translational indices of trauma-, stressor-, and anxiety-related behaviors (2014) · cites this paper as [67]
In the citing paper
“The rationale for selecting 50 mg as the dose was that this dose showed efficacy in previous work examining exposure enhancement with pre-session administration of DCS (10, 11).”
From D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia (2013) · cites this paper as [10]
In the citing paper
“In humans, DCS administration can likewise facilitate the loss of fear resulting from exposure that causes incomplete fear loss in controls (acrophobia: Ressler, Rothbaum, Tannenbaum, Anderson, Graap, Zimand, Hodges, & Davis, 2004; social phobia: Guastella, Richardson, Lovibond, Rapee, Gaston, Mitchell, & Dadds, 2008; Hofmann, Meuret, Smits, Simon, Pollack, Eisenmenger, Shiekh, & Otto, 2006;”
From D-cycloserine facilitates context-specific fear extinction learning (2008) · cites this paper as Ressler, Rothbaum, Tannenbaum, Anderson, Graap, Zimand, Hodges, & Davis, 2004
In the citing paper
“Indeed, in clinical studies, Ressler et al (2004) and Hofmann et al (2006) have recently reported that DCS facilitates fear extinction in patients with anxiety disorders.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al, 2004
In the citing paper
“This, considered collectively with findings from animal studies, leads to the postulation that DCS administration without extinction training cannot facilitate fear extinction.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al, 2004
In the citing paper
“Heresco-Levy et al (2002) used daily chronic dosing without exposure therapy, while Hofmann et al (2006) and Ressler et al (2004) used acute dosing with exposure therapy.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al (2004)
Citations
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
Manual for the state-trait anxiety inventory (form Y) : "self-evaluation questionnaire"
Spielberger, C. D., Gorsuch, R. L., & Lushene, R. E. (1970) · Consulting Psychologists Press eBooks · Cited by 2,352
Genetic enhancement of learning and memory in mice
Tang, Y., Shimizu, E., Dubé, G., Rampon, C., Kerchner, G. A., Zhuo, M., Liu, G., & Tsien, J. Z. (1999) · Nature · doi:10.1038/43432 · Cited by 1,878
Context, ambiguity, and unlearning: sources of relapse after behavioral extinction
Bouton, M. E. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01546-9 · Cited by 1,662
Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000) · JAMA · doi:10.1001/jama.283.19.2529 · Cited by 953
Behavioral and Neural Analysis of Extinction
Myers, K. M., & Davis, M. (2002) · Neuron · doi:10.1016/s0896-6273(02)01064-4 · Cited by 918
Self-citationMiserendino, M. J. D., Sananes, C. B., Melia, K. R., & Davis, M. (1990) · Nature · doi:10.1038/345716a0 · Cited by 824
Self-citationWalker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Self-citationEffectiveness of computer-generated (virtual reality) graded exposure in the treatment of acrophobia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.4.626 · Cited by 694
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,000
Hogle, J. M., Kaye, J. T., & Curtin, J. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.003 · Cited by 72
Yang, Y.-L., Chao, P.-K., Ro, L., Wo, Y., & Lu, K.-T. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301215 · Cited by 79
Minshawi, N. F., Wink, L. K., Shaffer, R. C., Plawecki, M. H., Posey, D. J., Liu, H., Hurwitz, S., McDougle, C. J., Swiezy, N. B., & Erickson, C. A. (2016) · Molecular Autism · doi:10.1186/s13229-015-0062-8 · Cited by 75
Testing the effects of Δ9-THC and D-cycloserine on extinction of conditioned fear in humans
Klumpers, F., Denys, D., Kenemans, J. L., Grillon, C., van der Aart, J., & Baas, J. M. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431624 · Cited by 72
D-Cycloserine Effects on Extinction of Conditioned Responses to Drug-Related Cues
Myers, K. M., & Carlezon, W. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.02.030 · Cited by 72
Kilaru, V., Iyer, S. V., Almli, L. M., Stevens, J. S., Lori, A., Jovanović, T., Ely, T. D., Bradley, B., Binder, E. B., Koen, N., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.69 · Cited by 71
Self-citationHillman, B. G., Gupta, S. C., Stairs, D. J., Buonanno, A., & Dravid, S. M. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.01.008 · Cited by 73
Novel NMDA receptor modulators: an update
Santangelo, R., Acker, T. M., Zimmerman, S. S., Katzman, B. M., Strong, K. L., Traynelis, S. F., & Liotta, D. C. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.728587 · Cited by 72
Yamada, D., Zushida, K., Wada, K., & Sekiguchi, M. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.86 · Cited by 72
Medial prefrontal cortex stimulation modulates the processing of conditioned fear
Guhn, A., Dresler, T., Andreatta, M., Müller, L. D., Hahn, T., Tupak, S. V., Polak, T. T., Deckert, J., & Herrmann, M. J. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00044 · Cited by 76
Ho, Y., Ho, S.-C., Pawlak, C. R., & Yeh, K.-Y. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.01.028 · Cited by 73
Woods, A. M., & Bouton, M. E. (2008) · Learning & Memory · doi:10.1101/lm.1078508 · Cited by 70
Jacobson, L. H., Bettler, B., Kaupmann, K., & Cryan, J. F. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0631-9 · Cited by 72
d-Cycloserine augmentation of cognitive remediation in schizophrenia
Cain, C. K., McCue, M. G., Bello, I., Creedon, T. B., Tang, D., LASKA, E. M., & GOFF, D. C. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.01.016 · Cited by 75
Enhancement of psychosocial treatment with D-cycloserine: Models, moderators, and future directions
Otto, M. W., Kredlow, M. A., Smits, J. A. J., Hofmann, S. G., Tolin, D. F., de Kleine, R. A., van Minnen, A., Evins, A. E., & Pollack, M. H. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.09.007 · Cited by 70
D-cycloserine potentiates the reconsolidation of cocaine-associated memories
Lee, J. L. C., Gardner, R. J., Butler, V. J., & Everitt, B. J. (2009) · Learning & Memory · doi:10.1101/lm.1186609 · Cited by 70
Insel, T. R., Sahakian, B. J., Voon, V., Nye, J. S., Brown, V. J., Altevogt, B. M., Bullmore, E. T., Goodwin, G. M., Howard, R. J., Kupfer, D. J., et al. (2012) · Nature · doi:10.1038/483269a · Cited by 70
Influence of ethanol withdrawal on fear memory: Effect of d-cycloserine
Bertotto, M. E., Bustos, S. G., Molina, V. A., & Martijena, I. D. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.07.013 · Cited by 70
Cholinergic blockade frees fear extinction from its contextual dependency
Zelikowsky, M., Hast, T. A., Bennett, R. Z., Merjanian, M., Nocera, N. A., Ponnusamy, R., & Fanselow, M. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.08.006 · Cited by 71
Evidence-Based Treatment of Post-Traumatic Stress Disorder
Difede, J., Olden, M., & Cukor, J. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-051812-145438 · Cited by 70
Bontempo, A., Panza, K. E., & Bloch, M. H. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11r07356 · Cited by 69
RANDOMIZED TRIAL OF D-CYCLOSERINE ENHANCEMENT OF COGNITIVE-BEHAVIORAL THERAPY FOR PANIC DISORDER
Otto, M. W., Pollack, M. H., Dowd, S. M., Hofmann, S. G., Pearlson, G. D., Szuhany, K. L., Gueorguieva, R. V., Krystal, J. H., Simon, N. M., & Tolin, D. F. (2016) · Depression and Anxiety · doi:10.1002/da.22531 · Cited by 69
From Extinction Learning to Anxiety Treatment: Mind the Gap
Carpenter, J. K., Pinaire, M., & Hofmann, S. G. (2019) · Brain Sciences · doi:10.3390/brainsci9070164 · Cited by 77
Virtual Reality as a Tool for Delivering PTSD Exposure Therapy and Stress Resilience Training
Rizzo, A., John, B., Newman, B., Williams, J., Hartholt, A., Lethin, C., & Buckwalter, J. G. (2012) · Military Behavioral Health · doi:10.1080/21635781.2012.721064 · Cited by 69
Modulation of Fear and Anxiety by the Endogenous Cannabinoid System
Chhatwal, J. P., & Ressler, K. J. (2007) · CNS Spectrums · doi:10.1017/s1092852900020939 · Cited by 71
Self-citationDadds, M. R., & Rhodes, T. (2008) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2008.0029 · Cited by 69
Circuit dysregulation and circuit-based treatments in posttraumatic stress disorder
Sheynin, J., & Liberzon, I. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2016.11.014 · Cited by 68
“Among strategies targeting fear circuits, pharmacological interventions with compounds like d-cycloserine, a partial NMDA agonist, in combination with exposure therapy, have been shown to facilitate fear extinction in phobic patients [64].”
BackgroundCognitive enhancers for anxiety disorders
Hofmann, S. G., Smits, J. A. J., Asnaani, A., Gutner, C. A., & Otto, M. W. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.11.020 · Cited by 69
Substance use disorders and schizophrenia: A question of shared glutamatergic mechanisms
Coyle, J. T. (2006) · Neurotoxicity Research · doi:10.1007/bf03033359 · Cited by 71
Research in anxiety disorders: From the bench to the bedside
Garner, M. J., Möhler, H., Stein, D. J., Mueggler, T., & Baldwin, D. S. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.01.011 · Cited by 71
Meyerbröker, K., Powers, M. B., van Stegeren, A. H., & Emmelkamp, P. M. G. (2011) · Psychotherapy and Psychosomatics · doi:10.1159/000329454 · Cited by 69
Medial prefrontal cortex activation facilitates re-extinction of fear in ratsPreprint
Chang, C., & Maren, S. (2011) · Learning & Memory · doi:10.1101/lm.2070111 · Cited by 73
The pharmacological management of childhood anxiety disorders: a review
Reinblatt, S. P., & Riddle, M. A. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0644-4 · Cited by 67
Social anxiety and posttraumatic stress symptoms: The impact of distressing social events
Carleton, R. N., Peluso, D. L., Collimore, K. C., & Asmundson, G. J. G. (2010) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2010.08.002 · Cited by 67
Cognitive function as an emerging treatment target for marijuana addiction.
Sofuoglu, M., Sugarman, D. E., & Carroll, K. M. (2010) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0019295 · Cited by 66
Pharmacological enhancement of exposure-based treatment in PTSD: a qualitative review
de Kleine, R. A., ROTHBAUM, B. O., & van Minnen, A. (2013) · European Journal of Psychotraumatology · doi:10.3402/ejpt.v4i0.21626 · Cited by 72
Self-citationThe effects of noradrenergic blockade on extinction in humans
Bos, M. G. N., Beckers, T., & Kindt, M. (2012) · Biological Psychology · doi:10.1016/j.biopsycho.2012.01.007 · Cited by 73
Augmentation of Cognitive Behavioral Therapy with Pharmacotherapy
Ganasen, K. A., Ipser, J., & Stein, D. J. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2010.04.008 · Cited by 68
A window of vulnerability: Impaired fear extinction in adolescence
Baker, K., Den, M. L., Graham, B. M., & Richardson, R. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.10.009 · Cited by 73
Neria, Y. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20121727 · Cited by 66
ROTHBAUM, B. O. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07121871 · Cited by 66
Self-citationKiefer, F., Kirsch, M., Bach, P., Hoffmann, S., Reinhard, I., Jorde, A., von der Goltz, C., Spanagel, R., Mann, K. F., Loeber, S., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3882-5 · Cited by 68
Pharmacologic management of comorbid post-traumatic stress disorder and addictions
Shorter, D. I., Hsieh, J. J., & Kosten, T. R. (2015) · American Journal on Addictions · doi:10.1111/ajad.12306 · Cited by 65
Mataix‐Cols, D., Turner, C. M., Monzani, B. A., Isomura, K., Murphy, C., Krebs, G., & Heyman, I. (2013) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.113.126284 · Cited by 64
Langton, J. M., & Richardson, R. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.32 · Cited by 63
A mismatch-based model for memory reconsolidation and extinction in attractor networks
Osan, R., Tort, A. B. L., & Amaral, O. B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023113 · Cited by 63
Davis, M. L., Witcraft, S. M., Baird, S. O., & Smits, J. A. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803457-6.00003-9 · Cited by 73
Self-citationFujita, Y., Morinobu, S., Takei, S., Fuchikami, M., Matsumoto, T., Yamamoto, S., & Yamawaki, S. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.01.026 · Cited by 66
Mühlberger, A., Wieser, M. J., & Pauli, P. (2007) · Biological Psychology · doi:10.1016/j.biopsycho.2007.09.004 · Cited by 63
Raber, J., Arzy, S., Bertolus, J. B., Depue, B., Haas, H. E., Hofmann, S. G., Kangas, M., Kensinger, E., Lowry, C. A., Marusak, H. A., et al. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.03.015 · Cited by 62
“(Hofmann et al., 2006; Ressler et al., 2004), some more recent findings suggest that DCS may be ineffective or even more harmful by enhancing reconsolidation of the fear memory rather than the extinction memory (Bolkan and Lattal, 2014; Lee et al.”
From Engrams to Pathologies of the Brain
Denny, C. A., Lebois, E. P., & Ramirez, S. (2017) · Frontiers in Neural Circuits · doi:10.3389/fncir.2017.00023 · Cited by 65
Glutamatergic agents for OCD and related disorders
Pittenger, C. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0051-8 · Cited by 62
Attention training for reducing spider fear in spider-fearful individuals
Reese, H. E., McNally, R. J., Najmi, S., & Amir, N. (2010) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2010.04.006 · Cited by 63
Singewald, N., Sartori, S. B., Reif, A., & Holmes, A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109418 · Cited by 64
Myers, K. M., & Carlezon, W. A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.015 · Cited by 61
Activation Mechanisms of the NMDA Receptor
VanDongen, A. M. J., & Blanke, M. L. (2008) · Frontiers in neuroscience · doi:10.1201/9781420044157.ch13 · Cited by 61
Enantioselective Synthesis of DialkylatedN-Heterocycles by Palladium-Catalyzed Allylic Alkylation
Numajiri, Y., Jiménez‐Osés, G., Wang, B., Houk, K. N., & Stoltz, B. M. (2015) · Organic Letters · doi:10.1021/ol503425t · Cited by 60
Management of methamphetamine abuse and dependence
Ling, W., Rawson, R., & Shoptaw, S. (2006) · Current Psychiatry Reports · doi:10.1007/s11920-006-0035-x · Cited by 60
Lost in translation: How to upgrade fear memory research
Flores, Á., Fullana, M. À., Soriano-Mas, C., & Andero, R. (2018) · Molecular Psychiatry · doi:10.1038/s41380-017-0006-0 · Cited by 59
d-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders
Hofmann, S. G., Wu, J. Q., & Boettcher, H. (2013) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-3-11 · Cited by 59
Pharmacological Treatment of Obsessive-Compulsive Disorder
Simpson, H. B. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_12 · Cited by 59
Effects of pharmacological manipulations of NMDA-receptors on deliberation in the Multiple-T task
Blumenthal, A., Steiner, A. P., Seeland, K. D., & Redish, A. D. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.01.011 · Cited by 61
Cognitive remediation in the treatment of stimulant abuse disorders: A research agenda.
Vocci, F. J. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0014101 · Cited by 62
Genheimer, H., Andreatta, M., Asan, E., & Pauli, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-18183-3 · Cited by 65
Shaw, J., Brown, R. F., & Dunn, S. M. (2015) · Patient Education and Counseling · doi:10.1016/j.pec.2015.08.023 · Cited by 58
Animal Models of Deficient Sensorimotor Gating in Schizophrenia: Are They Still Relevant?
Swerdlow, N. R., & Light, G. A. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_5012 · Cited by 63
Cognitive enhancers for facilitating drug cue extinction: Insights from animal models
Dhonnchadha, B. Á. N., & Kantak, K. M. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.01.018 · Cited by 57
McGuire, J. F., Lewin, A. B., & Storch, E. A. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.934677 · Cited by 57
“[32] found no significant difference between participants receiving different DCS dosages, Ressler et al.”
BackgroundResultInfluentialBattaglia, S., Fazio, C. D., Vicario, C. M., & Avenanti, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065926 · Cited by 56
Maddox, S. A., Schafe, G. E., & Ressler, K. J. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00062 · Cited by 60
Self-citationNMDA neurotransmission as a critical mediator of borderline personality disorder
Grosjean, B., & Tsai, G. E. (2007) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0710 · Cited by 57
New Insights into the Pathophysiology and Treatment of Fibromyalgia
Schmidt‐Wilcke, T., & Diers, M. (2017) · Biomedicines · doi:10.3390/biomedicines5020022 · Cited by 57
The Role of Serine Racemase in the Pathophysiology of Brain Disorders
Coyle, J. T., & Balu, D. T. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.10.002 · Cited by 58
Tailoring therapeutic strategies for treating posttraumatic stress disorder symptom clusters
Norrholm, S., & Jovanovic, T. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s10951 · Cited by 56
STEINGLASS, J., SYSKO, R., SCHEBENDACH, J., BROFT, A., STROBER, M., & WALSH, B. T. (2007) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000281484.89075.a8 · Cited by 56
Frewen, P., Dozois, D. J. A., & Lanius, R. A. (2010) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.8.1.foc92 · Cited by 56
Wolitzky-Taylor, K. B., & Telch, M. J. (2008) · Behavior Therapy · doi:10.1016/j.beth.2007.12.006 · Cited by 63
Pharmacological enhancement of fear reduction: preclinical models
Graham, B. M., Langton, J. M., & Richardson, R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01175.x · Cited by 57
Combining pharmacotherapy with cognitive behavioral therapy: Traditional and new approaches
Davis, M., Barad, M., Otto, M. W., & Southwick, S. (2006) · Journal of Traumatic Stress · doi:10.1002/jts.20149 · Cited by 55
Self-citationJacobson, L. H., Kelly, P. H., Bettler, B., Kaupmann, K., & Cryan, J. F. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.2076-06.2006 · Cited by 56
Advances in the treatment of anxiety: Targeting glutamate
Simon, A. B., & Gorman, J. M. (2006) · NeuroRx · doi:10.1016/j.nurx.2005.12.005 · Cited by 58
Impaired fear extinction in adolescent rodents: Behavioural and neural analyses
Baker, K., Bisby, M. A., & Richardson, R. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.05.019 · Cited by 60
How stress and glucocorticoids timing-dependently affect extinction and relapse
Drexler, S. M., Merz, C. J., Jentsch, V. L., & Wolf, O. T. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.12.029 · Cited by 63
Kuriyama, K., Honma, M., Soshi, T., Fujii, T., & Kim, Y. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2353-x · Cited by 54
Mechanisms of Action in Exposure Therapy
Knowles, K. A., & Tolin, D. F. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01391-8 · Cited by 54
Doctors’ experience of stress during simulated bad news consultations
Shaw, J., Brown, R. F., Heinrich, P., & Dunn, S. M. (2013) · Patient Education and Counseling · doi:10.1016/j.pec.2013.06.009 · Cited by 59
Extinction of drug seeking: Neural circuits and approaches to augmentation
McNally, G. P. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.06.007 · Cited by 56
D-cycloserine and cocaine cue reactivity: preliminary findings
Price, K. L., McRae-Clark, A. L., Saladin, M. E., Maria, M. M. M.-S., DeSantis, S. M., Back, S. E., & Brady, K. T. (2009) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990903384332 · Cited by 54
Sahakian, B. J., & Morein‐Zamir, S. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00004-8 · Cited by 55
Otto, M. W., Tolin, D. F., Nations, K. R., Utschig, A. C., Rothbaum, B. O., Hofmann, S. G., & Smits, J. A. J. (2012) · Depression and Anxiety · doi:10.1002/da.21910 · Cited by 54
Self-citationOtto, M. W., Basden, S. L., Leyro, T. M., McHugh, R. K., & Hofmann, S. G. (2007) · CNS Spectrums · doi:10.1017/s1092852900020526 · Cited by 53
Price, K. L., Baker, N. L., McRae‐Clark, A. L., Saladin, M. E., DeSantis, S. M., Ana, E. J. S., & Brady, K. T. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2592-x · Cited by 55
175 Years of Progress in PTSD Therapeutics: Learning From the Past
Stein, M. B., & ROTHBAUM, B. O. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17080955 · Cited by 57
Self-citationRiley, E., Mitko, A., Stumps, A. D., Robinson, M. E., Milberg, W., McGlinchey, R. E., Esterman, M. S., & Degutis, J. M. (2019) · Neuropsychology · doi:10.1037/neu0000529 · Cited by 52
Recent Advances in the Understanding and Treatment of Anxiety Disorders
Shearer, S. L. (2007) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2007.05.002 · Cited by 54
Neural Underpinnings of Fear and Its Modulation: Implications for Anxiety Disorders
Miller, L. A., Taber, K. H., Gabbard, G. O., & Hurley, R. A. (2005) · Journal of Neuropsychiatry · doi:10.1176/jnp.17.1.1 · Cited by 52
Judo, C., Matsumoto, M., Yamazaki, D., Hiraide, S., Yanagawa, Y., Kimura, S., Shimamura, K., & Togashi, H. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.06.035 · Cited by 52
Wang, A., Liou, Y., Pawlak, C. R., & Ho, Y. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.11.006 · Cited by 52
Augmentation of Fear Extinction by D-Cycloserine is Blocked by Proteasome Inhibitors
Mao, S.-C., Lin, H., & Gean, P. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.30 · Cited by 51
Rosenfield, D., Smits, J. A. J., Hofmann, S. G., Mataix‐Cols, D., de la Cruz, L. F., Andersson, E., Rück, C., Monzani, B. A., Pérez-Vigil, A., Frumento, P., et al. (2019) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2019.102149 · Cited by 52
Self-citation
Metadata
- Authors
- Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M.
- Affiliations
- Emory University (US)
- Virtually Better (US)
- University of North Carolina at Charlotte (US)
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2004-11-01
- Volume
- 61
- Issue
- 11
- Pages
- 1136
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2156900283
- Cited by
- 1,063
- References
- 45
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 14 · 2023: 17 · 2022: 54 · 2021: 20 · 2020: 20 · 2019: 31 · 2018: 35 · 2017: 53 · 2016: 30 · 2015: 52 · 2014: 62 · 2013: 74 · 2012: 79
- FWCI
- 82.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH-047840, MH069884, K01MH069884)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Keywords
- D-cycloserine, acrophobia, specific phobia, NMDA receptor partial agonist, fear extinction, virtual reality exposure therapy, nootropic drugs, adjunctive pharmacotherapy, skin conductance, anxiety disorders, fear learning, avoidance behavior, medication adherence
- MeSH terms
- Adult, Combined Modality Therapy, Cycloserine, Desensitization, Psychologic, Double-Blind Method, Extinction, Psychological, Fear, Female, Humans, Male, Middle Aged, Phobic Disorders, Pilot Projects, Placebos, Psychiatric Status Rating Scales, Receptors, N-Methyl-D-Aspartate, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
